© 1995 by Oxford University Press
Journal of the National Cancer Institute, Vol. 87, No. 16, 1237-1245,
August 16, 1995
© 1995 Oxford University Press
Vascular Permeability Factor (Vascular Endothelial Growth Factor) Expression and Angiogenesis in Cervical Neoplasia
Department of Pathology, Beth Israel Hospital and Harvard Medical School Boston MA.
*Correspondence to: Lawrence F. Brown, M.D., Beth Israel Hospital, Department of Pathology, 330 Brookline Ave., Boston, MA 02215.
Background: Angiogenesis is a critical factor in the progression of solid tumors, including cervical cancers. The mechanisms reponsible for angiogenesis in cervical neoplasia, however, are not well defined. Purpose: Our goal was to determine the relationship between angiogenesis and the expression of the angiogenic cytokine vascular permeability factor (VPF), also known as vascular endothelial growth factor, and its receptors in cervical neoplasia. Methods: Sixtysix cervical biopsy specimens were evaluated; among these, 16 samples were designated as benign, 17 as low-grade squamous intraepithelial lesions, 18 as high-grade squamous intraepithelial lesions, and 15 as invasive squamous cell carcinomas. Histologic sections immunostained for factor VIIIrelated antigen were evaluated quantitatively for microvessel density and for the presence of epithelial stromal vascular cuffing. Sections were also evaluated for VPF messenger RNA (mRNA) expression by in situ hybridization. Results: VPF mRNA expression, epithelial stromal vascular cuffing, and microvessel density counts were significantly increased in invasive carcinoma and in high-grade intraepithelial lesions as compared with lowgrade intraepithelial lesions and benign squamous epithelium. Vascular cuffing and increased microvessel density counts were also significantly associated with increased VPF mRNA expression. Conclusions: These observations suggest that VPF is an important angiogenic factor in cervical neoplasia. [J Natl Cancer Inst 87:1237-1245,1995]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S.-G. Yeo, J.-S. Kim, M.-J. Cho, K.-H. Kim, and J.-S. Kim Interstitial Fluid Pressure as a Prognostic Factor in Cervical Cancer Following Radiation Therapy Clin. Cancer Res., October 1, 2009; 15(19): 6201 - 6207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bhattacharya, J. Kwon, X. Li, E. Wang, S. Patra, J. P. Bida, Z. Bajzer, L. Claesson-Welsh, and D. Mukhopadhyay Distinct role of PLC{beta}3 in VEGF-mediated directional migration and vascular sprouting J. Cell Sci., April 1, 2009; 122(7): 1025 - 1034. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. I. Rini and W.K. Rathmell Biological Aspects and Binding Strategies of Vascular Endothelial Growth Factor in Renal Cell Carcinoma Clin. Cancer Res., January 15, 2007; 13(2): 741s - 746s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Branca, C Giorgi, D Santini, L Di Bonito, M Ciotti, A Benedetto, P Paba, S Costa, D Bonifacio, P Di Bonito, et al. Aberrant expression of VEGF-C is related to grade of cervical intraepithelial neoplasia (CIN) and high risk HPV, but does not predict virus clearance after treatment of CIN or prognosis of cervical cancer J. Clin. Pathol., January 1, 2006; 59(1): 40 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Smola-Hess, J. Pahne, C. Mauch, P. Zigrino, H. Smola, and H. J. Pfister Expression of membrane type 1 matrix metalloproteinase in papillomavirus-positive cells: role of the human papillomavirus (HPV) 16 and HPV8 E7 gene products J. Gen. Virol., May 1, 2005; 86(5): 1291 - 1296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Herbst and A. B. Sandler Non-Small Cell Lung Cancer and Antiangiogenic Therapy: What Can Be Expected of Bevacizumab? Oncologist, June 1, 2004; 9(suppl_1): 19 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Laitakari, V Nayha, and F Stenback Size, shape, structure, and direction of angiogenesis in laryngeal tumour development J. Clin. Pathol., April 1, 2004; 57(4): 394 - 401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Nayha, J. Laitakari, and F. Stenback Stage-Dependent Expression of an Angiogenic Agent and Vascular Organization in Experimental Skin Tumor Development Toxicol Pathol, August 1, 2003; 31(5): 539 - 548. [Abstract] [PDF]
|
|
|
|
 |
|
 H. F. Dvorak Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy J. Clin. Oncol., November 1, 2002; 20(21): 4368 - 4380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Molica, A. Vacca, D. Ribatti, A. Cuneo, F. Cavazzini, D. Levato, G. Vitelli, L. Tucci, A. M. Roccaro, and F. Dammacco Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia Blood, October 16, 2002; 100(9): 3344 - 3351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Rice and C M Quinn Angiogenesis, thrombospondin, and ductal carcinoma in situ of the breast J. Clin. Pathol., August 1, 2002; 55(8): 569 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. Miller, C. J. Sweeney, and G. W. Sledge Jr Redefining the Target: Chemotherapeutics as Antiangiogenics J. Clin. Oncol., February 15, 2001; 19(4): 1195 - 1206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Shiose, T. Sakamoto, H. Yoshikawa, Y. Hata, Y. Kawano, T. Ishibashi, H. Inomata, K. Takayama, and H. Ueno Gene Transfer of a Soluble Receptor of VEGF Inhibits the Growth of Experimental Eyelid Malignant Melanoma Invest. Ophthalmol. Vis. Sci., August 1, 2000; 41(9): 2395 - 2403. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. E. Favoni and A. De Cupis The Role of Polypeptide Growth Factors in Human Carcinomas: New Targets for a Novel Pharmacological Approach Pharmacol. Rev., June 1, 2000; 52(2): 179 - 206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Fujimoto, H. Sakaguchi, I. Aoki, and T. Tamaya Clinical Implications of Expression of Interleukin 8 Related to Angiogenesis in Uterine Cervical Cancers Cancer Res., May 1, 2000; 60(10): 2632 - 2635. [Abstract] [Full Text]
|
|
|
|
|
|
L. Hefler, C. Tempfer, A. Obermair, K. Frischmuth, G. Sliutz, A. Reinthaller, S. Leodolter, and C. Kainz Serum Concentrations of Vascular Endothelial Growth Factor in Vulvar Cancer Clin. Cancer Res., October 1, 1999; 5(10): 2806 - 2809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Molnar, I. Fekete, K. E. Schlageter, G. D. Lapin, and D. R. Groothuis Absence of Host-Site Influence on Angiogenesis, Blood Flow, and Permeability in Transplanted RG-2 Gliomas Drug Metab. Dispos., September 1, 1999; 27(9): 1085 - 1091. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Mesiano, N. Ferrara, and R. B. Jaffe Role of Vascular Endothelial Growth Factor in Ovarian Cancer : Inhibition of Ascites Formation by Immunoneutralization Am. J. Pathol., October 1, 1998; 153(4): 1249 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. F. Brown, A. J. Guidi, K. Tognazzi, and H. F. Dvorak Vascular Permeability Factor/Vascular Endothelial Growth Factor and Vascular Stroma Formation in Neoplasia: Insights from In Situ Hybridization Studies J. Histochem. Cytochem., May 1, 1998; 46(5): 569 - 576. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. O SCHLINGEMANN and V. W M VAN HINSBERGH Role of vascular permeability factor/vascular endothelial growth factor in eye disease Br J Ophthalmol, June 1, 1997; 81(6): 501 - 512. [Full Text] [PDF]
|
|